Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raltegravir in HIV-1 Infected Russian Children and Adolescents
NCT01717287Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2012
- Primary completion
- Dec 2013
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of raltegravir in human immunodeficiency virus type 1 infection (HIV-1), sponsored by Merck & Co.. Started Nov 2012; status: completed.
02
Drugs
raltegravir
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT01717287.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01717287.